SCHEMBL5409270

SCHEMBL5409270

O=C(O)CCN(Cc1ccccc1)C(=O)c1ccccc1-c1ccccc1C(=O)NCc1c(F)cccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HTT P42858 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
HDAC1 Q13547 3/20 0.41
HDAC6 Q9UBN7 2/20 0.41
KMT2A Q03164 2/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
MAPK14 Q16539 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409729 0.95 CYP1A2 (0.47) TDP1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL5409280 0.91 RAB9A (0.44) TDP1CYP1A2CYP2C19HTTCHRNB2
SCHEMBL5393984 0.91 HDAC1 (0.49) TDP1HDAC1HDAC6KMT2ARAB9A
SCHEMBL5392891 0.91 KMT2A (0.51) HTTKMT2ATSHRKCNA5MAPK1
SCHEMBL5402400 0.90 RAB9A (0.44) TDP1CYP1A2CYP2C19HTTCHRNB2
SCHEMBL5392697 0.89 KCNA5 (0.48) TDP1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL5400848 0.88 CHRNB2 (0.57) HTTCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5399679 0.86 LPAR1 (0.47) CYP1A2CYP2C19CHRNB2CHRNB4CHRNA3
SCHEMBL5399681 0.86 KMT2A (0.54) CYP1A2CYP2C19HTTCHRNB2CHRNB4
SCHEMBL5398638 0.86 KMT2A (0.54) CYP1A2CYP2C19HTTCHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB TDP1 1939/4885CYP1A2 2649/4885CYP2C19 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.